Download 1 Cancer Policy Roundtable (CPR) November 5

Cancer Policy Roundtable (CPR)
November 5-6, 2014
Washington, DC
Fairmont Hotel
Wednesday, November 5, 2014
8:00am-8:45am
Registration and Breakfast
Executive Forum Foyer
8:45am-9:00am
Welcome and Introductions
Executive Forum
Shelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition for Cancer Survivorship
9:00am-11:00am
Communication of Cancer Care Costs to Patients
A number of oncologists, other health care providers, and medical specialty
societies have recently recommended that there be much more explicit
communication with cancer patients about the cost of their care. Much of the
discussion has focused on communication with patients regarding the cost of
cancer drugs or the value of cancer drugs. This panel will focus on this new
paradigm of open communication with cancer patients regarding cost of care
and will consider a wide range of issues that arise in connection with cost
communication.
Panelists
Patricia M. Danzon, PhD
Celia Moh Professor of Health Care Management
The Wharton School
University of Pennsylvania
Jennifer Malin, MD, PhD
Medical Director for Oncology and Care Management
WellPoint, Inc.
Carol Marcusen, LCSW, MSW, BCD
Director, Social Services
USC/Norris Comprehensive Cancer Center Chair
1
Therese Mulvey, MD, FASCO
Physician-in-Chief
Southcoast Centers for Cancer Care
Thomas Smith, MD
Henry J. Duffey Family Professor of Palliative Care
School of Medicine
Johns Hopkins University
Susan L. Weiner, PhD
Founder and President
Children’s Cause for Cancer Advocacy
Moderator
Peter A. Ubel, MD
Professor of Business Administration and Medicine
Sanford School of Public Policy
Duke University
11:00am-11:30am
Break
11:30am-1:00pm
Medicare Data Release and its Implications for the Cancer Care System
In April 2014, the Centers for Medicare & Medicaid Services (CMS) released a
data set of physician payment and charge data, a move the agency described as
part of the Obama Administration’s efforts “to make our healthcare system
more transparent, affordable, and accountable.” The data release has been
both applauded and roundly criticized. Champions see the data as the
beginning of a new era of transparency in the health care system, while critics
say the data are misleading and incomplete. This panel will consider the risks
and benefits — to patients, physicians, third-party payers, and the entire health
system — of the Medicare data release and what additional data are necessary
for a fair comparison on physicians and their care delivery.
Panelists
Leah Binder, MA, MGA
President & CEO
The Leapfrog Group
Reshma Jagsi, MD, DPhil
Associate Professor, Department of Radiation Oncology
Research Investigator, Center for Bioethics and Social Sciences in Medicine.
University of Michigan Health System
Michael Kolodziej, MD
National Medical Director
Oncology Strategies
Aetna
2
Therese Mulvey, MD, FASCO
Physician-in-Chief
Southcoast Centers for Cancer Care
Moderator
Lee Newcomer, MD, MHA
Senior Vice President
Oncology, Genetics and Women’s Health
UnitedHealthcare
1:00pm-2:00pm
Lunch
Roosevelt
2:00pm-3:30pm
The Physician Payments Sunshine Act and its Impact on Cancer Care, Research,
and Education
Executive Forum
The Physician Payments Sunshine Act is intended to bring greater transparency
to the financial relationships that exist among manufacturers, physicians, and
teaching hospitals. Under the terms of the law, which created the Open
Payments Program at the Centers for Medicare & Medicaid Services,
pharmaceutical and device companies began to report their payments to
physicians and teaching hospitals on August 1, 2013. The panel will consider the
intent of the law, how it may achieve its intended purpose of greater
transparency, how it is affecting relationships among pharmaceutical and device
companies and health care providers, and the burdens of reporting.
Panelists
Shantanu Agrawal, MD
Deputy Administrator and Director, Center for Program Integrity
Centers for Medicare & Medicaid Services
Ashish Kalgaonkar, MBA
Senior Director, Global HCP Transparency Reporting
Eli Lilly and Company
Blase Polite, MD, MPP
Assistant Professor of Medicine
The University of Chicago
James M. (Mit) Spears, JD
General Counsel
PhRMA
Moderator
Neil M. Kirschner, PhD
Senior Associate, Regulatory and Insurer Affairs
American College of Physicians
3
3:30pm-4:00pm
Break
4:00pm-5:30pm
Transparency in the Relationships Between Patient Advocacy Organizations
and their Corporate Funders
Advocacy organizations that are actively involved in public policy advocacy and
that accept funding from corporate funders find themselves at risk of criticism
that their policies regarding conflicts of interest are not sufficiently rigorous.
Even as advocacy groups develop their own conflicts policies, those entities that
offer them funding are imposing new reporting requirements. In addition,
federal agencies that welcome comment from patient advocates during
regulatory meetings, including advisory committees related to specific products,
have established policies for patient advocates’ disclosure of funding
relationships. The panel will discuss the conflict of interest policies that have
been developed by non-profit cancer advocacy organizations and how the
organizations implement and adhere to those standards and to the
requirements of federal agencies, their funders, and other private organizations
regarding transparency and disclosure.
Panelists
Lisa C. Keenan, JD
Counsel
Venable LLP
Sheila Rothman, PhD, MSW
Mailman School of Public Health
Columbia University
Fran Visco, JD
President
National Breast Cancer Coalition
Moderator
Shelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition for Cancer Survivorship
5:30pm
Reception
Sulgrave Room
Thursday, November 6, 2014
8:30am-9:00am
Registration and Breakfast
Executive Forum Foyer
9:00am-10:00am
Keynote Presentation
Executive Forum
4
Joshua M. Sharfstein, MD
Secretary
Maryland Department of Health and Mental Hygiene
10:00am-10:15am
Break
10:15am-11:45am
Enhancing the Sharing of Patient-Specific Research Data
In recent months, the Food and Drug Administration (FDA), National
Institutes of Health (NIH), and individual research entities have been
deliberating strategies for strengthening the sharing of patient-specific
clinical trials data and the Institute of Medicine (IOM) has identified
principles for data-sharing. New approaches to sharing of data may
have important implications for cancer research and care. The panel will
discuss the potential benefits and possible risks of sharing clinical trials
data as well as various efforts to establish appropriate standards for
such data-sharing initiatives.
Panelists
Justin McCarthy, JD
Senior Vice President, Global Policy & International Public Affairs
Pfizer
Lou Staudt, MD, PhD
Director, Center for Cancer Genomics
National Cancer Institute
John J. Whyte, MD, MPH
Director of Professional Affairs and Stakeholder Engagement
Center for Drug Evaluation and Research
Food and Drug Administration
John Wilbanks
Chief Commons Officer
Sage Bionetworks
Moderator
Louise M. Perkins, PhD
Chief Science Officer
Melanoma Research Alliance
11:45am-12:00pm
Closing Remarks and Adjourn
Shelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition for Cancer Survivorship
5